BLOCKADE OF PALLIDAL ADENOSINE A<sub>2A</sub> RECEPTORS POTENTIATES CONTRALATERAL ROTATIONAL BEHAVIOR INDUCED BY L-DOPA AND DOPAMINERGIC AGONISTS IN HEMIPARKINSONIAN RATS

Nicola Simola<sup>a</sup>, Sandro Fenu<sup>a</sup>, Pier G. Baraldi<sup>b</sup>, Mojgan A. Tabrizi<sup>b</sup> and Micaela Morelli<sup>a</sup>

<sup>a</sup>Department of Toxicology and Centre of Excellence for Neurobiology of Dependence, University of Cagliari, Cagliari, Italy; <sup>b</sup>Department of Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy

The globus pallidus (GP), one of the main projection areas of the striatum, is the principal component of the basal ganglia circuitry. There is growing evidence that the adenosine A<sub>2A</sub> receptor serves to play a crucial role in basal ganglia function, particularly in the control of motor behaviour; furthermore adenosine A<sub>2A</sub> antagonists have been shown to exhibit a prominent anti-Parkinsonian activity in several animal models. An involvement of GP in the antiparkinsonian effects of A2A receptor antagonists has been proposed on the basis of the selective localization of A<sub>2A</sub> receptors on the striatopallidal pathway. Evidence has shown that A<sub>2A</sub> receptors are expressed in GP at medium-high level; moreover, both adenosine A<sub>2A</sub> agonists and antagonists modulate the extracellular concentrations of GABA. Those studies suggest that, besides striatum, A<sub>2A</sub> receptor antagonists might exert their antiparkinsonian activity at the level of GP. The aim of this study was to investigate the effect of the intrapallidal infusion of SCH BT2, a water-soluble analogue of the A<sub>2A</sub> antagonist SCH 58261, on contralateral turning behavior, induced by dopamine receptor agonists, in the unilaterally 6-hydroxydopamine rat model of Parkinson’s Disease. SCH BT2 (5µg/1µl) altered neither motor behavior nor produced postural asymmetry by itself. However, when infused simultaneously with a parenteral subthreshold dose of L-DOPA (3 mg/kg i.p.) which elicited scarce contralateral rotational behavior (34.7±20.7/1h), SCH BT2 significantly potentiated the number of contraversive rotations (167.4±16.3/1h). SCH BT2 significantly potentiated quinpirole (0.05 mg/kg s.c.) induced turning behavior (45.3±16.5/1h vs 7.5±1.9/1h) and SKF 38393 (1.5 mg/kg s.c.) induced contraversive rotations (812±109/3h vs 314.4±127/3h). These results indicate that blockade of pallidal A<sub>2A</sub> receptors enhances the behavioral effects of dopamine receptor stimulation in 6-OHDA-lesioned rats, suggesting that GP may be involved in the antiparkinsonian effects of A<sub>2A</sub> antagonists. Furthermore, the potentiation of D<sub>1</sub>-mediated effects observed, suggests that the GP may be a central area in the basal ganglia circuit for modulation of both D<sub>1</sub> and D<sub>2</sub> mediated motor responses.